Siglec and anti-Siglec therapies
- PMID: 33607404
- DOI: 10.1016/j.cbpa.2021.01.001
Siglec and anti-Siglec therapies
Abstract
Siglecs (sialic acid-binding immunoglobulin-like lectins) are a family of receptors that bind sialic acids in specific linkages on glycoproteins and glycolipids. Siglecs play roles in immune signalling and exhibit cell-type specific expression and endocytic properties. Recent studies suggest that Siglecs are likely to function as immune checkpoints that regulate responses in cancers and inflammatory diseases. In this review, we discuss strategies to target the Siglec-sialic acid axis in human diseases, particularly cancer, and the possibility of exploiting them for therapeutic intervention.
Keywords: Cancer; Immune checkpoint; Inflammation; Sialic acid; Siglec.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest PRC is a scientific cofounder and Scientific Advisory Board member of Palleon Pharmaceuticals. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
